Dimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Dimensional Fund Advisors LP lowered its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 532,742 shares of the company's stock after selling 216,250 shares during the period. Dimensional Fund Advisors LP owned 1.03% of 4D Molecular Therapeutics worth $11,182,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. RA Capital Management L.P. grew its stake in 4D Molecular Therapeutics by 21.3% in the 1st quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company's stock valued at $160,941,000 after buying an additional 888,300 shares in the last quarter. Janus Henderson Group PLC grew its stake in 4D Molecular Therapeutics by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 3,197,444 shares of the company's stock valued at $101,844,000 after buying an additional 104,148 shares in the last quarter. Vanguard Group Inc. grew its position in shares of 4D Molecular Therapeutics by 25.3% during the 1st quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company's stock valued at $74,551,000 after purchasing an additional 473,094 shares in the last quarter. Redmile Group LLC purchased a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at $40,189,000. Finally, Goldman Sachs Group Inc. grew its position in shares of 4D Molecular Therapeutics by 415.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company's stock valued at $16,539,000 after purchasing an additional 658,069 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on FDMT. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Chardan Capital boosted their price target on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. Leerink Partners reaffirmed an "outperform" rating and set a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 22nd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.25.

Insider Activity at 4D Molecular Therapeutics

In related news, CEO David Kirn sold 12,923 shares of the business's stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total transaction of $290,638.27. Following the transaction, the chief executive officer now owns 1,059,153 shares in the company, valued at $23,820,350.97. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Scott Bizily sold 1,750 shares of the company's stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $27.11, for a total value of $47,442.50. Following the transaction, the insider now owns 6,781 shares in the company, valued at approximately $183,832.91. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David Kirn sold 12,923 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total transaction of $290,638.27. Following the transaction, the chief executive officer now owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,169 shares of company stock worth $396,146 over the last 90 days. 7.30% of the stock is owned by company insiders.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock traded down $0.68 during mid-day trading on Monday, hitting $9.29. The company's stock had a trading volume of 318,440 shares, compared to its average volume of 907,725. The stock has a market cap of $480.32 million, a price-to-earnings ratio of -4.01 and a beta of 2.77. The business has a 50 day moving average price of $14.45 and a 200-day moving average price of $21.14. 4D Molecular Therapeutics, Inc. has a 12 month low of $9.28 and a 12 month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.90 million. On average, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.